Education
About Us
Working with TipRanks
Follow Us
Prothena (DE:0PT)
FRANKFURT:0PT
0PT Stock Chart & Stats
€7.25
€0.00(0.00%)
At close: 4:00 PM EST
€7.25
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.86 - €15.20
Previous CloseN/A
Volume0.00
Average Volume (3M)27.00
Market Cap
€400.75M
Enterprise Value€155.17M
Total Cash (Recent Filing)€330.84M
Total Debt (Recent Filing)€9.08M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Feb 12, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,829,983
10 Day Avg. Volume81
30 Day Avg. Volume27
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.53
Price to Sales (P/S)5.51
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.77Price Target Upside158.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Coramitug Mechanism And Biomarker ValidationClinical biomarker improvements that align with an amyloid‑clearing mechanism support coramitug as a differentiated candidate in the ATTR space and may increase confidence in future hard‑endpoint trials.
CYTOPE Intracellular Delivery BreakthroughPreclinical data showing systemic, non‑lytic intracellular delivery that clears pathogenic aggregates and corrects RNA dysfunction highlights a potentially transformative platform for targeting previously undruggable proteins.
Partnerships & Late‑stage ProgramsPartnered programs with large biopharma advancing into phase three enhance development credibility and could attract capital and licensing interest through external validation.
Bears Say
Analyst Sentiment RiskAn analyst's reiteration of an Underperform rating can exert downward pressure by signaling professional skepticism and discouraging risk‑sensitive investors.
Competitive Market PositioningCoramitug could face limited uptake if it becomes a later‑line therapy in an already crowded treatment landscape, constraining commercial potential.
Parkinson's Development RiskPrior failure of a similar program and the historical difficulty of demonstrating phase three efficacy in Parkinson's disease raise concerns about the probability of success for related late‑stage programs.
Prothena News
0PT FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was €3.86 and its highest was €15.20 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is €400.75M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Feb 12, 2026 which is today.
How were Prothena’s earnings last quarter?
Currently, no data Available
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.47.
How many shares outstanding does Prothena have?
Prothena has 53,829,983 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in DE:0PT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€18.77 (158.93% Upside)
€18.77 (158.93% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.42%
12-Months-Change
Fundamentals
Return on Equity
-67.63%
Trailing 12-Months
Asset Growth
-40.76%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
0PT Stock 12 Month Forecast
Average Price Target
€18.77
▲(158.93% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Xoma
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Options Prices
Currently, No data available
---